Biocon Limited announced its consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a total income of ₹4,423 crore, with EBITDA at ₹865 crore. Net profit for the period stood at ₹41 crore, a decrease of 52% year-on-year. The press release also highlighted key business achievements, including progress in biosimilars and partnerships.
Biocon Announces Q2 FY27 Financial Performance
Biocon Limited has released its financial results for the quarter and half-year ended September 30, 2026. The company posted a total income of ₹4,423 crore for the second quarter of fiscal year 2027, marking a 1% increase compared to ₹4,389 crore in the same period last year. EBITDA for the quarter was reported at ₹865 crore, a 7% decrease from ₹928 crore in Q2 FY26.
Profitability and Key Financials
The net profit after exceptional items for Q2 FY27 was ₹41 crore, down 52% from ₹85 crore reported in Q2 FY26. Profit Before Tax (PBT) before exceptional items stood at ₹62 crore, a significant decrease from ₹183 crore in the prior year’s quarter. Net profit before exceptional items was ₹44 crore, compared to ₹92 crore in Q2 FY26.
Biopharma Segment Performance
The Biopharma segment, comprising biosimilars and generics, saw its revenue increase by 5% year-on-year to ₹3,583 crore in Q2 FY27. Biosimilars revenue grew 3% to ₹2,809 crore, while Generics revenue increased by 10% to ₹774 crore. Services revenue experienced a 13% quarter-on-quarter growth, reaching ₹833 crore.
Strategic Partnerships and Business Highlights
A significant business development highlighted in the release is the securing of a landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil, valued at approximately USD 400 million. The company also noted progress in its global commercialization efforts, including for biosimilar Pertuzumab in Europe and the US market expansion for Yesafili™ and Yesintek®.
Leadership Commentary
Kiran Mazumdar-Shaw, Executive Chairperson, expressed confidence in Biocon’s long-term growth trajectory, citing industry firsts in biosimilars and global manufacturing excellence. Shreehas Tambe, CEO & Managing Director, emphasized the company’s strategic priorities and progress, particularly highlighting the global settlement for Pebrilzo® and the Pertuzumab partnership in Brazil.
Syngene Performance Update
Syngene International Limited reported a 13% sequential revenue growth in Q2 FY27, driven by its CDMO business. However, year-on-year revenue declined 9%. The company also highlighted the signing of its first manufacturing agreement for the Bayview biologics facility in the US.
Balance Sheet Overview
As of September 30, 2026, Biocon’s total assets stood at ₹65,280 crore, an increase from ₹63,636 crore as of March 31, 2026. Total equity was ₹37,156 crore, and total liabilities amounted to ₹28,124 crore.
Source: BSE
